Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Summary not available.
Natera (NASDAQ: NTRA) will present updated analyses from the phase III ALTAIR trial at ASCO GI (Jan 8–10, 2026). A post‑hoc blinded central radiographic review reclassified cases and showed a statistically significant disease‑free survival (DFS) benefit for Trifluridine/Tipiracil (FTD/TPI) versus placebo in Signatera‑positive colorectal cancer patients (median DFS 9.23 vs 5.55 months; HR 0.75, 95% CI: 0.55–0.98; P=0.0406). This result updates a prior overall ALTAIR analysis that was numerically improved but not statistically significant. Natera will also present data on Signatera velocity showing ~40% shorter RFS with ctDNA doubling ≤1 month.
Natera (NASDAQ: NTRA) launched an expanded 21-gene Fetal Focus single-gene NIPT powered by LinkedSNP technology, backed by prospective blinded data from the EXPAND trial.
In 294 total samples across 21 genes, the test demonstrated 96% sensitivity (24/25 affected pregnancies) and 98% population-weighted specificity. In a new 193-sample cohort covering 16 added genes, Fetal Focus showed 100% sensitivity (14/14) and 94.2% observed specificity. EXPAND has enrolled >1,800 participants and includes diagnostic confirmation for all positive and negative cases. The test is presented as an option when partner carrier testing is unavailable after a positive carrier screen.
Natera (NASDAQ: NTRA) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 13, 2026 at 4:30 p.m. PT (7:30 p.m. ET). Management will deliver a presentation and host a Q&A with the investment community. A live webcast will be available via the company's investor relations site at investor.natera.com, and a replay will be posted shortly after the event.
Natera (NASDAQ: NTRA) announced publication in JAMA Oncology of a randomized phase III CALGB (Alliance)/SWOG 80702 analysis of Signatera ctDNA in stage III colorectal cancer (940 patients with post-surgical plasma). Key findings: in Signatera-positive patients, adding celecoxib to FOLFOX lowered recurrence and death risk by ~40% (DFS adjusted HR=0.61; OS adjusted HR=0.62) with 3-year DFS 41.0% vs 22.6% and 5-year OS 61.6% vs 39.9%. No significant benefit was seen in Signatera-negative patients. A QC-restricted subgroup (66%) showed stronger benefit (adjusted HR=0.49); Natera reports 99% routine QC pass rate.
Natera (NASDAQ: NTRA) and collaborators published I‑SPY 2 results in Nature Communications showing Signatera personalized ctDNA testing can refine risk stratification in 723 women with high‑risk, early‑stage breast cancer treated with neoadjuvant therapy (NAT).
Key findings: Signatera improved prognostic precision beyond residual cancer burden (RCB) for RCB‑II/III patients; post‑NAT ctDNA– patients had substantially higher 3‑year distant recurrence‑free survival (e.g., RCB‑II T3 88% vs 57%; RCB‑III T3 83% vs 22% for ctDNA– vs ctDNA+). Persistent post‑NAT ctDNA+ predicted recurrence (adjusted HR 5.20, p < 0.001). Median assay variant conservation was 94–97% between pretreatment and post‑NAT samples.
Natera (NASDAQ: NTRA) and MEDSIR announced the MiRaDoR phase II multicenter trial (NCT05708235) testing Signatera Genome‑guided interventions in early‑stage HR+/HER2‑ breast cancer.
Up to 60 Signatera‑positive patients without radiologic recurrence will be sequentially assigned to four arms: standard endocrine therapy (90 days) then switch to Arm B giredestrant, Arm C giredestrant+abemaciclib, or Arm D giredestrant+inavolisib for PIK3CA‑mutant patients. Primary endpoint: proportion with ≥90% ctDNA decrease/clearance at 3 months. Enrollment is underway with UK sites active and further European activations expected in 2026.
Natera (NASDAQ: NTRA) reported initial translational results from the Phase III PALLAS trial showing that Signatera MRD testing after surgery strongly stratifies distant recurrence risk in stage II–III HR+/HER2- breast cancer.
In a U.S. biomarker cohort of 420 patients, ~92% were MRD-negative at baseline with a 5-year DRFI of 93%, while baseline MRD-positive (~8%) had a 5-year DRFI of 28% (HR ~15). At end of treatment, MRD-negative 5-year DRFI was 95% and MRD-positive 32% (HRs >20). MRD status at baseline, ~6 months, and EOT was consistently highly prognostic versus clinicopathologic factors.
Natera (NASDAQ: NTRA) presented two oral analyses at the ASH Annual Meeting showing clinical utility of personalized ctDNA testing in lymphoma.
Key highlights: Signatera detected ctDNA pre-treatment in 94% of 144 patients across 14 lymphoma subtypes and showed ctDNA clearance strongly predicted CAR-T response (p=0.0028); rapid clearance after one chemotherapy cycle had HR 20.95 versus 7.45 for delayed clearance. Signatera end-of-1L status was highly prognostic for event-free survival (HR 49.77, p<0.0001). The HOVON study using CLARITY (166 DLBCL patients) found post-negative surveillance relapse-free probability of 99% at 6 months and 97% at 12 months.
Natera (NASDAQ: NTRA) completed an all-stock acquisition of Foresight Diagnostics to expand its personalized MRD offerings and lymphoma capabilities. The deal values Foresight at up to $450 million ( $275M upfront plus $175M in earnouts tied to revenue and reimbursement milestones). Foresight’s PhasED-Seq phased-variant technology reports LOD95 of 0.3 ppm and detection below 0.1 ppm, and the technology will be integrated into Natera’s Signatera platform for research use immediately and for clinical launch in 2026. Foresight CLARITY MRD assay and recent inclusion of ctDNA MRD in NCCN lymphoma guidance support clinical momentum.